Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487124 | 0.88 | SYK (0.43) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL17909879 | 0.83 | SRC (0.40) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL21292981 | 0.81 | BACE1 (0.39) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL18425042 | 0.77 | KMO (0.39) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL17909883 | 0.77 | SYK (0.38) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL17909776 | 0.74 | SRC (0.39) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL16881110 | 0.74 | AR (0.46) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL27907482 | 0.71 | MEN1 (0.54) | SRCKDRPOLBNTRK1PIM1 | |
| SCHEMBL21292982 | 0.71 | HPGD (0.48) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL21292970 | 0.71 | HPGD (0.39) | SRCPIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981893-B2 | Therapeutic inhibitory compounds | SERPINB1, KLKB1, SERPINE1 | SRC 3710/4885PIK3CD 1401/4885ABL1 1224/4885 |
| US-20190263783-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | SERPINB1, KLKB1, SERPINE1 | SRC 1795/4885PIK3CD 1114/4885ABL1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.